Replies to post #7679 on Advantego Corporation (ADGO)

[xr_biotech_consult]

no bid soon, soon increase the Company's authorized capitalization to 15,000,000,000 shares of common stock. def14

Cash & cash equivalents $ 19,368
Total Liabilities $ 4,380,741

REVENUES
Sales $ 55,114 Three Months Ended September

Common stock, par value $.0001 per share; shares 2,000,000,000 authorized; 33,384,036 issued and outstanding

billions of Shares will be dumped.


the Company will pay a sales commission to Aska equal to 98% of the revenues received from the sales to Aska’s existing clients in North America in which revenue from those clients was approximately $13,922,000 (unaudited). As of the date of this commission has not been paid and no revenues or costs have been accounted for.

gl